FDA reports lowest Q1 inspection count for biologics companies in Delaware

In Delaware, the FDA inspected one Biologics company in the first quarter of 2026, according to the U.S. Food and Drug Administration (FDA).

This represented the fewest inspections for any company type conducted by the FDA in Delaware, accounting for 14.3% of all inspections during that period.

The FDA routinely inspects facilities across the nation to determine if the workplace and their products are compliant with FDA-regulated laws and regulations implemented to improve overall public health. Inspection results are then disclosed publicly.

According to its website, the FDA is a government agency that is primarily responsible for monitoring the production and distribution of human and animal drugs, biological products, medical supplies and tobacco products for safety and quality.